MAT stands for medication-assisted treatment, a approach to treating substance use disorders that combines FDA-approved medications with counseling and behavioral therapy. The goal is to treat the whole person, not just the physical dependence. MAT is used primarily for opioid use disorder and alcohol use disorder, and the specific medications differ depending on which substance a person is struggling with.
How MAT Works
Substance use disorders change brain chemistry in ways that make willpower alone insufficient for most people. MAT medications work by interacting with the same receptors in the brain that drugs and alcohol affect. Some activate those receptors at a lower, controlled level to reduce cravings and withdrawal. Others block the receptors entirely so the substance no longer produces a high. The medication handles the biological side of addiction while counseling addresses the behavioral and psychological side.
Medications for Opioid Use Disorder
The FDA has approved three medications for opioid use disorder: buprenorphine, methadone, and naltrexone. Each works differently, and the right choice depends on where someone is in their recovery.
Buprenorphine
Buprenorphine is a partial agonist, meaning it activates opioid receptors in the brain but only partially. This produces enough of an effect to ease cravings and prevent withdrawal symptoms without delivering the full high of heroin or prescription painkillers. It comes as a film or tablet dissolved under the tongue, or as a long-acting injection given under the skin. Because it has a ceiling effect, taking more beyond a certain dose doesn’t increase its effects, which makes it harder to misuse than full opioids.
Since 2023, any healthcare provider with a standard DEA registration that includes Schedule III authority can prescribe buprenorphine for opioid use disorder. Previously, providers needed a special waiver (known as the X-waiver), which created a significant bottleneck in access. That requirement was eliminated by the Consolidated Appropriations Act of 2023. Providers applying for or renewing their DEA registration now need at least eight hours of training on substance use disorders, or board certification in addiction medicine.
Methadone
Methadone is a full agonist. It fully activates opioid receptors but does so slowly and steadily, preventing the intense rush associated with heroin or fentanyl. It comes as an oral tablet or liquid concentrate. Unlike buprenorphine, methadone can only be dispensed through certified opioid treatment programs, which means patients typically visit a clinic daily to receive their dose, at least in the early stages of treatment. This structure provides accountability but can also be a barrier for people with jobs, childcare responsibilities, or limited transportation.
Naltrexone
Naltrexone takes the opposite approach. It’s an antagonist, meaning it blocks opioid receptors entirely. If someone takes an opioid while on naltrexone, they won’t feel the effects. For opioid use disorder, it’s given as a monthly injection. The catch is that a person must be fully detoxed from opioids before starting naltrexone. If any opioids are still in the system, naltrexone can trigger severe withdrawal.
Medications for Alcohol Use Disorder
Three medications are also FDA-approved for alcohol use disorder, and they’ve been available for decades.
Naltrexone, the same medication used for opioid addiction, also works for alcohol dependence. It reduces the pleasurable effects of drinking by blocking the brain’s reward response to alcohol. It’s available as a daily pill or a monthly injection. The FDA approved the oral version in 1994 and the injectable form in 2006.
Acamprosate, approved in 2004, works differently. It helps restore the chemical balance in the brain that heavy, prolonged drinking disrupts. It’s most useful for people who have already stopped drinking and want to maintain sobriety, as it reduces the lingering discomfort and anxiety that can drive relapse.
Disulfiram was the first medication approved for alcohol dependence and stood alone for over 40 years before naltrexone arrived. It works through deterrence: if you drink while taking disulfiram, you’ll experience nausea, flushing, and vomiting. The unpleasant reaction is the point. It doesn’t reduce cravings, so it works best for people who are highly motivated and have support to ensure they take it consistently.
How Effective MAT Is
For opioid use disorder, the evidence is strong. Staying on methadone or buprenorphine is associated with substantial reductions in the risk of death from all causes, including overdose. The flip side is equally telling: over 80% of people on methadone who stop taking it return to using heroin within one year. This isn’t a failure of the medication. It reflects how deeply opioid dependence reshapes brain function and why most guidelines recommend long-term treatment.
MAT also improves treatment retention, which matters because staying engaged with any form of treatment is one of the strongest predictors of long-term recovery. People on MAT are more likely to keep attending counseling, maintain employment, and avoid criminal justice involvement compared to those attempting abstinence-only approaches.
How Long Treatment Lasts
There is no fixed endpoint for MAT. All 11 national clinical guidelines across North America, Australia, and the UK recommend long-term treatment with no explicit stopping point. Five of those guidelines suggest staying on medication for at least one year before even considering tapering, though no strong evidence supports a specific timeline.
People in the first two years of treatment are less likely to consider tapering, partly because the medication is actively keeping cravings manageable. The ideal time to begin reducing medication, if ever, depends on individual factors: how severe the addiction was, how stable someone’s housing and finances are, whether they have family support, and how well they’re doing in counseling. Because the risk of relapse and overdose rises significantly after stopping medication, clinical guidelines generally discourage tapering. When patients do want to taper, shared decision-making between the patient and provider is the recommended approach.
Why It’s Called “Medication-Assisted”
The name itself is a source of some debate. “Medication-assisted” implies the medication plays a supporting role, with counseling and therapy as the main event. In practice, for opioid use disorder especially, the medication is often the most critical component. Some clinicians and organizations now prefer the term MOUD (medications for opioid use disorder) to reflect that medication isn’t just an add-on but a core treatment. Regardless of the label, the combination of medication with behavioral support remains the standard of care and the approach with the strongest evidence behind it.